Resverlogix’ RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
CALGARY, Apr. 23, 2012 /CNW-AsiaNet/ –
This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic
TSX Exchange Symbol: RVX
ResRead More…
Tag: Resverlogix Corp.
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
CALGARY, Alberta, Canada, Apr. 19, 2012 /CNW-AsiaNet/ –
Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX Resverlogix CoRead More…